Azidothymidine treatment of hepatocellular carcinoma in rats: An in vivo study of telomerase inhibition

Hepato-Gastroenterology

Volumn 58, Issue 112, 2011, Pages 2091-2096

  Jeng, Kuo Shyang ^a   Sheen, I Shyan ^b   Jeng, Wen Juei ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Growth; Hepatocellular carcinoma; Metastasis; Progression; Telomerase inhibition

Indexed keywords

DIETHYLNITROSAMINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROTEIN BCL 2; TELOMERASE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL RAT; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; GENES, BCL-2; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; RATS, INBRED LEW; RNA, MESSENGER; TELOMERASE; ZIDOVUDINE;

EID: 84857677413     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11087     Document Type: Article

References (48)

1. Blackburn EH: Structure and function of telomeres. Nature 1991; 350:569-571.
2. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW: Human RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1997; 56:645-650.
3. Bestilny LJ, Brown CB, Miura Y, Robertson LD, Riabowol KT: Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res 1996; 56:3796-3802. (Pubitemid 26272031)
4. Greider CW: Telomeres, telomerase and senescence. BioEssays 1990; 12:363-369.
5. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R: Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998; 58:622-625. (Pubitemid 28099468)
6. Wright WE, Shay JW, Piatyszek MA: Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 1995; 23:3794-3795.
7. Engelhard M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA: Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 1997; 90:182-193. (Pubitemid 27276561)
8. Lange T: Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 1994; 91:2882-2885.
9. Wright WE, Shay JW: Telomere positional effects and the regulation of cellular senescence. Trends Genet 1992; 8:193-197.
10. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR: Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14:4240-4248.
11. Shimada M, Hasegawa H, Gion T, Utsunomiya T, Shirabe K, Takenaka K: The role of telomerase activity in hepatocellular carcinoma. Am J Gastroenterol 2000; 95:748-752. (Pubitemid 30123914)
12. Saini N, Srinivasan R, Chawla Y, Sharma S, Chakraborti A, Rajwanshi A: Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int; 29:1162-1170.
13. Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M: Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 1997; 112:493-500. (Pubitemid 27078836)
14. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG: Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003; 63:579-585. (Pubitemid 36158134)
15. Brown T, Sigurdson E, Rogatko A, Broccoli D: Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol 2003; 10:910-915. (Pubitemid 40486856)
16. Tejera AM, Alonso DF, Gomez DE, Olivero OA: Chronic in vitro exposure to 3′-azido-2′, 3′-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells. Breast Cancer Res Treat 2001; 65:93-99. (Pubitemid 32193612)
17. Johnston JS, Johnson A, Gan Y, Wientjes MG, Au JL: Synergy between 3′-azido-3′-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res 2003; 20:957-961. (Pubitemid 36774264)
18. Chen Y, Kong Q: Nuclear translocation of telomerase reverse transcriptase: a critical process in chemical induced hepatocellular carcinogenesis. Neoplasma 2010; 57:222-227.
19. Nishikawa T, Nakajima T, Katagishi T, et al.: Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation. Liver Int 2009; 29:846-856.
20. Miura N, Osaki Y, Nagashima M, et al.: A novel biomarker TERT-mRNA is applicable for early detection of hepatoma. BMC Gastroenterol 2010; 10:46-57.
21. Greten TF, Forner A, Korangy F, N'Kontchou G, et al.: A phase H open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010; 10:209-215.
22. Liu H, Shi W, Luan F, et al.: Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus Genes 40:174-182.
23. Luan F, Liu H, Gao L, et al.: Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut; 58:1528-1537
24. Takahashi S, Kitamoto M, Takaishi H, Aikata H, Kawakami Y, Nakanishi T: Expression of telomerase component genes in hepatocellular carcinomas. Eur J Cancer 2000; 36:496-502. (Pubitemid 30136228)
25. Kishimoto K, Fujimoto J, Takeuchi M, Yamamoto H, Ueki T, Okamoto E: Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J Surg Oncol 1998; 69:119-124. (Pubitemid 28549885)
26. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E: Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995; 55:2734-2736.
27. Park YM, Choi JY, Byun BH, Cho CH, Kim HS, Kim BS: Telomerase is strongly activated in hepatocellular carcinoma but in chronic hepatitis and cirrhosis. Exp Mol Med 1998; 30:35-40. (Pubitemid 28181770)
28. Shay JW, Wright WE: The reactivation of telomerase activity in cancer progression. Trends Genet 1996; 12:129-131. (Pubitemid 26114764)
29. Nagao K, Tomimatsu M, Endo H, Hisatomi H, Hikiji K: Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol 1999; 34:83-87. (Pubitemid 29112340)
30. Ohta K, Kanamaru T, Morita Y, Hayashi Y, Ito H, Yamamoto M: Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence. J Gastroenterol 1997; 32:791-796. (Pubitemid 27524986)
31. Ohta K, Kanamaru T, Yamamoto M, Saitoh Y: Clinical significance of telomerase activity in hepatocellular carcinoma. Kobe J Med Sci 1996; 42:207-217.
32. Nouso K, Urabe Y, Higashi T, Nakatsukasa H, Hino N, Ashida K: Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma. Cancer 1996; 78:232-326.
33. Ogami M, Ikura Y, Nishiguchi S, Kuroki T, Ueda M, Sakurai M: Quantitative analysis and in situ localization of human telomerase RNA in chronic liver disease and hepatocellular carcinoma. Lab Invest 1999; 79:15-26. (Pubitemid 29063759)
34. Huang GT, Lee HS, Chen CH, Chiou LL, Lin YW, Lee CZ: Telomerase activity and telomere length in human hepatocellular carcinoma. Eur J Cancer 1998; 34:1946-1949. (Pubitemid 28535446)
35. Ohashi K, Tsutsumi M, Nakajima Y, Kobitsu K, Nakano H, Konishi Y: Telomere changes in human hepatocellular carcinomas and hepatitis virus infected noncancerous livers. Cancer (Supp 1) 1996; 77:1747-1751.
36. Zhang RG, Zhao JJ, Yang LQ, et al.: RNA interference-mediated hTERT inhibition enhances TRAlL-induced apoptosis in resistant hepatocellular carcinoma cells. Oncol Rep 2010; 23:1013-1019.
37. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281:1322-1326. (Pubitemid 28406819)
38. Hockenbery D, Nufiez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348:334-336. (Pubitemid 120029101)
39. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programmed cell death. Cell 1993; 74:609-619. (Pubitemid 23259742)
40. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997; 3:614-620.
41. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80:879-886.
42. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124:1-6.
43. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993; 361:365-368.
44. Lee GH: Correlation between Bcl-2 expression and histopathology in diethylnitrosamine-I nduced mouse hepatocellular tumors. Am J Pathol 1997; 151:957-961.
45. Iida A, Yamaguchi A, Hirose K: Telomerase activity in colorectal cancer and its relationship to bcl-2 expression. J Surg Oncol 2000; 73:219-223. (Pubitemid 30238414)
46. Elkak AE, Kirkpatrick K, Mears L, Wells C, Ghilchik M, Newbold R: Telomerase activity and Bcl-2 expression in human breast cancer. Eur J Surg Oncol 2002; 28:14-18. (Pubitemid 41122776)
47. Ohmura Y, Aoe M, Andou A, Shimizu N: Telomerase activity and Bcl-2 expression in non-small cell lung cancer. Clin Cancer Res 2000; 6:2980-2987. (Pubitemid 30637718)
48. Mandal M, Kumar R: Bcl-2 modulates telomerase activity. J Biol Chem 1997; 272:14183-14187. (Pubitemid 27232827)